S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:WVE

Wave Life Sciences (WVE) Stock Price, News & Analysis

$6.17
+0.13 (+2.15%)
(As of 03/28/2024 ET)
Today's Range
$5.89
$6.18
50-Day Range
$3.54
$6.84
52-Week Range
$3.15
$7.67
Volume
596,534 shs
Average Volume
1.38 million shs
Market Capitalization
$754.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Wave Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
45.9% Upside
$9.00 Price Target
Short Interest
Healthy
2.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
1.20mentions of Wave Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.94) to ($1.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

98th out of 939 stocks

Pharmaceutical Preparations Industry

37th out of 444 stocks

WVE stock logo

About Wave Life Sciences Stock (NASDAQ:WVE)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

WVE Stock Price History

WVE Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Wave Life Sciences: Q4 Earnings Snapshot
Wave Life Sciences Gains 34% On Narrower Loss In Q4
Wave Life Sciences Ltd. (WVE)
Watch Now: “The Longest Wave in Africa”
Leerink Partners Sticks to Its Buy Rating for Wave Life Sciences (WVE)
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/29/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:WVE
Employees
266
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$15.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+45.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-57,510,000.00
Pretax Margin
-51.36%

Debt

Sales & Book Value

Annual Sales
$113.31 million
Book Value
$0.40 per share

Miscellaneous

Free Float
84,254,000
Market Cap
$754.47 million
Optionable
Optionable
Beta
-1.16
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Paul B. Bolno M.B.A. (Age 50)
    M.D., President, CEO & Director
    Comp: $1.1M
  • Mr. Kyle B. Moran CFA (Age 53)
    CFO & Principal Accounting Officer
    Comp: $677.87k
  • Dr. Chandra Vargeese Ph.D. (Age 63)
    Chief Technology Officer
    Comp: $710.05k
  • Kate Rausch
    Head of Investor Relations
  • Ms. Linda Rockett J.D.
    Senior VP & General Counsel
  • Dr. Christopher Francis Ph.D. (Age 46)
    Senior VP of Corporate Development & Head of Emerging Areas
    Comp: $493.13k
  • Ms. Daryn Lewis
    Senior VP & Head of Human Resources
  • Dr. Sridhar Vaddeboina Ph.D.
    Senior Vice President of Chemistry, Manufacturing & Controls
  • Ms. Anne-Marie Li-Kwai-Cheung
    Chief Development Officer
  • Dr. Hsiu-Chiung Yang Ph.D.
    Senior Vice President of Translational Medicine

WVE Stock Analysis - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares.
View WVE analyst ratings
or view top-rated stocks.

What is Wave Life Sciences' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $15.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for WVE
or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2024?

Wave Life Sciences' stock was trading at $5.05 at the start of the year. Since then, WVE shares have increased by 22.2% and is now trading at $6.17.
View the best growth stocks for 2024 here
.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our WVE earnings forecast
.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The firm earned $29.06 million during the quarter, compared to the consensus estimate of $23.30 million. During the same quarter last year, the company earned ($0.47) earnings per share.

What ETF holds Wave Life Sciences' stock?

iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include M28 Capital Management LP (7.44%), Primecap Management Co. CA (3.80%), Point72 Asset Management L.P. (3.24%), Price T Rowe Associates Inc. MD (1.64%), Price T Rowe Associates Inc. MD (1.64%) and Vanguard Group Inc. (1.33%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WVE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners